Mike Bayne

Poole, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.

Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.

Journal: Blood advances

Published: June 05, 2020

Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study.

Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study.

Journal: The British journal of dermatology

Published: May 30, 2020

Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.

Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.

Journal: The British journal of dermatology

Published: May 22, 2020

Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.

Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.

Journal: The British journal of dermatology

Published: April 29, 2019

The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients.

The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients.

Journal: The British journal of dermatology

Published: September 25, 2018

Ninety Day Mortality and Overall Survival after Radical Radiotherapy for Non-small Cell Lung Cancer.

Ninety Day Mortality and Overall Survival after Radical Radiotherapy for Non-small Cell Lung Cancer.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: November 01, 2017

COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.

COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 22, 2017

Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial.

Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial.

Journal: The Lancet. Oncology

Published: February 09, 2016

Recommendations for Radiotherapy Technique and Dose in Extra-nodal Lymphoma.

Recommendations for Radiotherapy Technique and Dose in Extra-nodal Lymphoma.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: May 21, 2015

Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.

Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 04, 2013

Erlotinib in the treatment of patients with multiple metastases from non-small cell lung cancer: clinical case selection for optimal response.

Erlotinib in the treatment of patients with multiple metastases from non-small cell lung cancer: clinical case selection for optimal response.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: January 27, 2013

The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: results of a prospective study with mature survival data.

The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: results of a prospective study with mature survival data.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: July 16, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026